Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction

Platelets

Volumn 24, Issue 7, 2013, Pages 528-537

  Funck Jensen, Kristian Lokke ^a   Dalsgaard, Jens ^a   Grove, Erik Lerkevang ^a   Hvas, Anne Mette ^a   Kristensen, Steen Dalby ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute myocardial infarction; Platelet aggregation; Platelet aggregation inhibitors; Platelet function tests; Platelet turnover

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL FRACTIONATION; CLINICAL TRIAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PLATELET TURNOVER; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; TURNOVER TIME;

AGED; ASPIRIN; BLOOD PLATELETS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 84884732213     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.738838     Document Type: Article

References (46)

1. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-2230
2. Wurtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010 Aug;3(8):828-835
3. Grove EL, Wurtz M, Hvas AM, Kristensen SD. Increased platelet turnover in patients with previous definite stent thrombosis. J Thromb Haemost 2011;9(7):1418-1419
4. Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011;123(16):1745-1756
5. Althoff TF, Fischer M, Langer E, Ziemer S, Baumann G. Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thromb Res 2010;125(5):e190-e196
6. Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005;3:10
7. Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Dosch C, Bigalke B, Langer H, Herdeg C, Gawaz M. Residual platelet activity is increased in clopidogrel-And ASA-Treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008;94(6):743-747
8. Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: Definitions, mechanisms and clinical importance. Curr Pharm Des 2012;18(33):5344-61
9. Brar SS, Ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, Disciascio G, Cuisset T, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-Analysis of individual participant data. J Am Coll Cardiol 2011;58(19):1945-1954
10. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-Analysis. BMJ 2008;336(7637):195-198
11. Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, Schomig E, Verheugt FW, ten Berg JM. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008;122(6):776-781
12. Nishiyama A, Niikawa O, Mohri H, Tsushima M. Timing of antiplatelet effect after oral aspirin administration in patients with sympathetic excitement. Circ J 2003;67(8):697-700
13. Pamukcu B, Oflaz H, Onur I, Cimen A, Nisanci Y. Effect of cigarette smoking on platelet aggregation. Clin Appl Thromb Hemost 2011;17(6):E175-E180
14. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. Circulation 1993;88(6):2728-2734
15. Grove EL, Kristensen SD. Update on oral antiplatelet therapy: Principles, problems and promises. Future Cardiol 2009;5(3):247-258
16. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009;101(1):151-156
17. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011;9(1):185-191
18. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007;5(3):490-496
19. Freynhofer MK, Bruno V, Brozovic I, Grove EL, Kristensen SD, Willheim M, Hubl W, Huber K. Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses. Thromb Haemost 2011;106(1):182-184
20. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, et al. Universal definition of myocardial infarction. Circulation 2007;116(22):2634-2653
21. von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and multiplate. Hamostaseologie 2007;27(3):155-160, quiz 161-162
22. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56(12):919-933
23. Coleman J, Wang J, Simon D. Determination of individual response to aspirin therapy using the accumetrics ultegra RPFAASA system. Point Care 2004;3:77-82
24. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: Impact on thrombosis and safety (GRAVITAS) trial. Circulation 2011;124(10):1132-1137
25. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17(3-4):317-327
26. Patrono C, Rocca B. Drug insight: Aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med 2007;4(1):42-50
27. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996;93(2):229-237
28. Wallentin L. P2Y(12) inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30(16):1964-1977
29. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schomig A, Schomig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92(2):311-316
30. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial. J Am Coll Cardiol 2006;48(5):931-938
31. Patrono C, Baigent C, Hirsh J, Roth G. American College of Chest Physicians. Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):199S-233S.
32. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978;61(2):314-319
33. Valles J, Santos MT, Fuset MP, Moscardo A, Ruano M, Perez F, Pinon M, Brena S, Aznar J. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2007;99(1):19-25
34. Poulsen TS, Kristensen SR, Korsholm L, Haghfelt T, Jorgensen B, Licht PB, Mickley H. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res 2007;120(4):477-484
35. Grove EL, Storey RF, Wurtz M, Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012;18(33):5379-91
36. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010;103(6):1245-1253
37. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28(14):1702-1708
38. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drugeluting stent implantation. Eur Heart J 2008;29(8):992-1000
39. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up. Circulation 2009;119(2):237-242
40. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-Term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306(11):1215- 1223
41. Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M, Dong JF, Kleiman NS, Guthikonda S. Platelet activation patterns in platelet size sub-populations: Differential responses to aspirin in vitro. J Thromb Thrombolysis 2010;30(3):251-262
42. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52(9):743-749
43. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008;99(5):930-935
44. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol 2001;24(11):701-704
45. Muller K, Aichele S, Herkommer M, Bigalke B, Stellos K, Htun P, Fateh-Moghadam S, May AE, Flather M, Gawaz M, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010;213(1):256-262
46. Assinger A, Schmid W, Volf I. Decreased VASP phosphorylation in platelets of male and female smokers of young age. Platelets 2010;21(8):596-603